These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10587038)

  • 1. Accrual issues for chemoprevention trials: the example of the 4-HPR study for the prevention of contralateral breast cancer.
    Camerini T; De Palo G; Mariani L; Marubini E; Costa A; Veronesi U
    Tumori; 1999; 85(4):299-303. PubMed ID: 10587038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
    De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
    J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of breast cancer with retinoids.
    Veronesi U; De Palo G; Costa A; Formelli F; Marubini E; Del Vecchio M
    J Natl Cancer Inst Monogr; 1992; (12):93-7. PubMed ID: 1535505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemoprevention of breast cancer with fenretinide.
    Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
    Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
    Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.
    Kumar N; Crocker T; Smith T; Pow-Sang J; Spiess PE; Egan K; Quinn G; Schell M; Sebti S; Kazi A; Chuang T; Salup R; Helal M; Zagaja G; Trabulsi E; McLarty J; Fazili T; Williams CR; Schreiber F; Slaton J; Anderson JK
    Contemp Clin Trials; 2012 Mar; 33(2):279-85. PubMed ID: 22101219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment strategy cost and impact on minority accrual to a breast cancer prevention trial.
    Dew A; Khan S; Babinski C; Michel N; Heffernan M; Stephan S; Jordan N; Jovanovic B; Carney P; Bergan R
    Clin Trials; 2013 Apr; 10(2):292-9. PubMed ID: 23321266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.
    Decensi A; Formelli F; Torrisi R; Costa A
    J Cell Biochem Suppl; 1993; 17G():226-33. PubMed ID: 8007703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of breast cancer.
    Costa A; Sacchini V; Bonanni B; D'Aiuto G
    Eur J Cancer Prev; 1994 Jul; 3(4):361-4. PubMed ID: 7950891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.